# A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

> **NCT02882087** · PHASE2 · TERMINATED · sponsor: **RemeGen Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Moderate and Severe Rheumatoid Arthritis

## Interventions

- **DRUG:** Placebo plus MTX
- **DRUG:** RC18 160 mg plus MTX

## Key facts

- **NCT ID:** NCT02882087
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2019-02-25
- **Final completion:** 2019-02-25
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** Lack of trial population, unable to recruit subjects
- **Last updated:** 2019-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02882087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02882087, "A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02882087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*